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Background: Accumulation of excess body fluid and autonomic dysregulation are clinically important characteristics of acute
decompensated heart failure. We hypothesized that transthoracic bioimpedance, a noninvasive, simple method for measuring
fluid retention in lungs, and heart rate variability, an assessment of autonomic function, can be used for detection of fluid
accumulation in patients with acute decompensated heart failure.
Objective: We aimed to evaluate the performance of transthoracic bioimpedance and heart rate variability parameters obtained
using a fluid accumulation vest with carbon black–polydimethylsiloxane dry electrodes in a prospective clinical study (System
for Heart Failure Identification Using an External Lung Fluid Device; SHIELD).
Methods: We computed 15 parameters: 8 were calculated from the model to fit Cole-Cole plots from transthoracic bioimpedance
measurements (extracellular, intracellular, intracellular-extracellular difference, and intracellular-extracellular parallel circuit
resistances as well as fitting error, resonance frequency, tissue heterogeneity, and cellular membrane capacitance), and 7 were
based on linear (mean heart rate, low-frequency components of heart rate variability, high-frequency components of heart rate
variability, normalized low-frequency components of heart rate variability, normalized high-frequency components of heart rate
variability) and nonlinear (principal dynamic mode index of sympathetic function, and principal dynamic mode index of
parasympathetic function) analysis of heart rate variability. We compared the values of these parameters between 3 participant
data sets: control (n=32, patients who did not have heart failure), baseline (n=23, patients with acute decompensated heart failure
taken at the time of admittance to the hospital), and discharge (n=17, patients with acute decompensated heart failure taken at
the time of discharge from hospital). We used several machine learning approaches to classify participants with fluid accumulation
(baseline) and without fluid accumulation (control and discharge), termed with fluid and without fluid groups, respectively.
Results: Among the 15 parameters, 3 transthoracic bioimpedance (extracellular resistance, R0; difference in
extracellular-intracellular resistance, R0 – R∞, and tissue heterogeneity, α) and 3 heart rate variability (high-frequency, normalized
low-frequency, and normalized high-frequency components) parameters were found to be the most discriminatory between groups
(patients with and patients without heart failure). R0 and R0 – R∞ had significantly lower values for patients with heart failure
than for those without heart failure (R0: P=.006; R0 – R∞: P=.001), indicating that a higher volume of fluids accumulated in the
lungs of patients with heart failure. A cubic support vector machine model using the 5 parameters achieved an accuracy of 92%
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for with fluid and without fluid group classification. The transthoracic bioimpedance parameters were related to intra- and
extracellular fluid, whereas the heart rate variability parameters were mostly related to sympathetic activation.
Conclusions: This is useful, for instance, for an in-home diagnostic wearable to detect fluid accumulation. Results suggest that
fluid accumulation, and subsequently acute decompensated heart failure detection, could be performed using transthoracic
bioimpedance and heart rate variability measurements acquired with a wearable vest.
(JMIR Med Inform 2020;8(8):e18715) doi: 10.2196/18715
KEYWORDS
heart failure; transthoracic bioimpedance; heart rate variability; fluid accumulation; autonomic nervous system; machine learning;
cardiology
Introduction
Heart failure is estimated to affect more than 25 million people
worldwide and over 6 million people in the United States [1-4].
Acute decompensated heart failure frequently results in
hospitalization and can also increase risk for arrhythmia, stroke,
and death [5,6]. The most clinically apparent features associated
with acute decompensated heart failure include pulmonary or
peripheral edema [5,7,8]. Several validated biomarkers for acute
decompensated heart failure detection exist, including body
weight, B-type natriuretic protein, invasive pulmonary pressure
measurement, and intrathoracic bioimpedance from cardiac
implantable devices [9]. The simplest, least costly, and most
widely used measure for ambulatory patients with chronic heart
failure is body weight; however, body weight monitoring is not
an ideal approach, since weight change correlates poorly with
acute heart failure worsening, thus limiting the impact of
existing home-based heart failure management programs [10].
Transthoracic bioimpedance can measure intrathoracic volume,
a surrogate biomarker of pulmonary edema [11-13]. For years,
it has been applied for lung fluid abnormality detection and
fluid management after heart failure [14,15]. Transthoracic
bioimpedance injects a small alternating current into the tissue
via electrodes and measures the voltage response. By doing so,
and by using Ohm’s law, the electrical resistance of the thorax
can be calculated. Higher values of resistance suggest lower
volumes of fluid accumulated in the lungs, and vice versa (for
a detailed technical explanation of transthoracic bioimpedance,
please see the Methods section). Electrocardiographic (ECG)
signals are used to compute parameters of heart rate variability
[16], which has been shown to be dysregulated in patients with
heart failure and provides information about the autonomic
nervous system [16-18].
Traditionally, various types of electrodes have been used for
transthoracic bioimpedance and ECG measurements using fluid
accumulation vests: adhesive Ag-AgCl electrodes, which often
result in skin irritation and are often misaligned when positioned;
textile electrodes, which need to be wetted prior to every use;
and recently proposed reusable carbon
black–polydimethylsiloxane (PDMS) dry electrodes [19,20].
In our previous work [19,20], we showed that carbon
black–PDMS electrodes could be a suitable alternative to textile
electrodes for measuring transthoracic bioimpedance and ECG
signals using customized fluid accumulation vests. Since these
electrodes are biocompatible, do not cause skin irritations, do
not need to be wetted prior to use, and show comparable results
to those of textile and adhesive electrodes, we decided to use
carbon black–PDMS dry electrodes.
There are several studies [12,21] that have explored
bioimpedance to detect acute decompensated heart failure. Our
group has shown that transthoracic bioimpedance can be
measured daily with fluid accumulation vests using conventional
electrodes, and a predictive algorithm analyzing daily
bioimpedance parameters showed reasonable performance in
predicting recurrent heart failure events, including
hospitalization, diuretic uptitration, and worsening heart failure
symptoms [12]. Lindholm et al [22] determined that leg
bioimpedance was inversely correlated with heart failure
incidence, and by combining leg bioimpedance with
demographic information, they obtained accurate heart failure
predictions. Sato et al [23] evaluated parameters from
bioelectrical impedance analysis in participants with congenital
heart disease and determined that the edema index obtained
from bioelectrical impedance analysis could also be a marker
for heart failure severity.
In this prospective clinical study (System for Heart Failure
Identification using an External Lung Fluid Device; SHIELD)
to examine the performance of transthoracic bioimpedance and
heart rate variability measured using carbon black–PDMS
electrodes embedded in fluid accumulation vests for detection
of acute decompensated heart failure, we hypothesized that (1)
participants without acute decompensated heart failure should
have resistance measurements that are higher than those of
participants with acute decompensated heart failure at the time
of admittance to the hospital; (2) participants with acute
decompensated heart failure at the time of discharge from
hospital should have smaller amount of accumulated lung fluid
and therefore higher resistance measurements than those of
participants with acute decompensated heart failure at the time
of admission; and (3) autonomic function assessed by heart rate
variability would provide additional information about the
dysregulation of heart failure patients, hence, it would detect
acute decompensated heart failure.
Methods
Experimental Setup
A total of 93 hospitalized individuals were prospectively
enrolled in our observational study at the University of
Massachusetts Medical Center. We acquired recordings from
participants with acute decompensated heart failure taken within
the first few hours of hospital arrival (baseline) and taken prior
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to discharge from hospital (discharge). We also acquired
recordings from a group of patients without acute
decompensated heart failure (control). All participants gave
written informed consent before participating in the study, in
accordance with the Declaration of Helsinki. The protocol was
approved by the institutional review board of the University of
Massachusetts Memorial Hospital (docket number H00014714).
The CONSORT diagram in Figure 1 depicts the screening and
enrollment process for this study. We screened over 800 people
for the heart failure group alone, which resulted in 432 people
identified with acute heart failure. Of these 432 people, only
142 were eligible. We had strict eligibility criteria for this study.
Exclusion criteria were patients with an implantable cardioverter
defibrillator or pacemaker, who were non-English speaking,
who were on dialysis, who had advanced cancer requiring
chemotherapy, or who did not have the ability to consent. Most
people were excluded from the study due to the presence of an
implantable cardioverter-defibrillator or pacemaker (130/290,
44.8%). Our inclusion criteria consisted of patients who were
aged over 40 years (50 years if enrolled before June 28, 2018);
who were on hospital-based telemetry; who had New York
Heart Association functional class II, III, or IV heart failure;
and whose skin was intact.
For this study, we used Philips prototype fluid accumulation
vests [12], which provide transthoracic bioimpedance
measurements at 16 frequencies in the range from 10 kHz to
999 kHz and ECG recordings at 256 Hz. Participants wore the
vest without clothing, so that its 4 electrodes were affixed to
their left and right abdomen. Copper mesh carbon black–PDMS
electrodes were used [24]. These electrodes have been proven
to provide consistent transthoracic bioimpedance and ECG
measurements when used with this vest [19]. For each recording,
participants were asked to sit still for 10 minutes while seated
on a chair with their legs resting on the floor. Once the recording
was completed, a device attached to the vest wirelessly
transmitted the data via a secure Bluetooth connection to a
mobile phone (Samsung Galaxy Gio GT-S5660). The data were
saved on an extractable secure digital memory card on the
mobile phone and subsequently transferred to a PC for
processing and analysis. Patients needed to be able to remain
seated for at least 15 minutes to participate in the study.
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Figure 1. CONSORT diagram. AF: atrial fibrillation; ESRD: end-stage renal disease; HF: heart failure; ICD: implantable cardioverter-defibrillator.
Transthoracic Bioimpedance Measurements
Transthoracic bioimpedance is a noninvasive method that
measures the impedance of the tissue at a series of frequencies.
A small alternating current, typically ranging from 100 µA to
10 mA, is injected into the tissue via electrodes, while the
voltage drop is measured as the output. By applying Ohm’s law,
the resistance of the body tissue can be calculated. Biological
tissue is typically modeled with a resistance R0 to represent the
extracellular fluid, in parallel with a resistance RI to represent
intracellular fluid, and a capacitance Cm to represent cell
membranes [17]. Electrical current with a frequency f=0 Hz
will pass around all cells, and the total resistance is equal to the
resistance from the extracellular fluid only, R0. At the other
extreme, when the frequency is infinite, f=∞, the current will
pass through the cells, and the total resistance can be calculated
as the parallel circuit of R0 and RI,
where RI can be represented as
If we measure impedance for frequencies between these two
extreme cases, we obtain an arc-like Cole-Cole plot in the
impedance plane [25-27]. The equation for the model of the
Cole-Cole plot [28,29] is
The parameters of the model can be extrapolated from a set of
measurements made at a predefined set of frequencies. The
exponent α represents the heterogeneity of the tissue in the
model. For each frequency, the real (resistance) and imaginary
(reactance) part of the electrical impedance is estimated. The
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Taubin algorithm [30] is used to fit a circle onto the measured
impedance data. From the data computed using the Taubin
algorithm, parameters of the Cole model are estimated using a
heuristic search method, the Nelder-Mead algorithm [31].
Figure 2 shows an illustrative example of a Cole-Cole plot for
one of the participants. The value of R0 is obtained as the x-axis
intercept at the far right side of the Cole-Cole plot, while the
value of R∞ is the x-axis intercept at the far left side of the same
plot. The frequency that corresponds to the upper point of the
circle is called the resonance frequency, fc,
The sum of the square error is minimized in the fitting process.
The fitting error was calculated as the sum of the square error
at the optimal parameters. We calculated 8 transthoracic
bioimpedance measurements in this study: R0, RI, R∞, R0 – R∞,
fc, Cm, α, and fitting error.
Figure 2. Illustrative example of the Cole-Cole plot of one patient.
Heart Rate Variability Measurements
To compute heart rate variability parameters, 4 minutes of clean
ECG data were extracted from each 5-minute recording of ECG
acquired simultaneously with transthoracic bioimpedance
measurements. Noise and motion artifacts were removed from
the ECG signals using a bandpass filter (0.05 Hz-40 Hz). The
R peaks were detected using a validated algorithm [32,33].
Segments were visually inspected to ensure correct heartbeat
detection. The R-R intervals were computed, and the time series
was transformed to an evenly sampled signal (sampling
frequency: 4 Hz) using cubic-spline interpolation. Mean heart
rate was computed as a parameter. A 256-point Blackman
window was applied to each segment, and the fast Fourier
transform was calculated for each windowed segment. Finally,
the power spectra of the segments were averaged.
We computed the indices of low frequencies of heart rate
variability (low-frequency components of heart rate variability:
0.045 Hz to 0.15 Hz), high frequencies of heart rate variability
(high-frequency components of heart rate variability: 0.15 Hz
to 0.4 Hz), and the indices normalized to the total power of heart
rate variability (normalized low-frequency components of heart
rate variability, normalized high-frequency components of heart
rate variability) [16]. Indices obtained from the low-frequency
components of heart rate variability represent sympathetic
control, and indices from the high-frequency components of
heart rate variability power represent parasympathetic control.
Furthermore, we derived 2 more parameters of heart rate
variability based on principal dynamic modes, a nonlinear
method designed to extract only the principal dynamic
components of the signal via eigendecomposition [18]. The
principal dynamic mode technique is able to separate
sympathetic (principal dynamic mode index of sympathetic
function) and parasympathetic (principal dynamic mode index
of parasympathetic function) dynamics from heart rate
variability [17,18]. Table 1 includes the parameters computed
in this study.
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Table 1. Transthoracic bioimpedance and heart rate variability parameters computed in this study.
DescriptionParameter
Transthoracic bioimpedance
Model resistance of biological tissue—extracellular fluid or resistance when f=0R 0
Model resistance of biological tissue—intracellular fluidR I
Resistance of biological tissue when f=∞R ∞
Range of x values in Cole-Cole plotR 0 –R ∞
Characteristic frequency, ie, frequency corresponding to the upper point of Cole-Cole plot circlef c
Cell membrane capacitanceC m
Exponent of the model representing tissue heterogeneityα
Sum of squared error of the optimal Cole-Cole plot modelFitting error
Heart rate variability
Low-frequency components of heart rate variability powerLFa HRVb
Normalized low-frequency components of heart rate variability powerNormalized LF HRV
High-frequency components of heart rate variability powerHFc HRV
Normalized high-frequency components of heart rate variability powerNormalized HF HRV
Sympathetic function heart rate variability dynamicsPDMI sympatheticd
Parasympathetic function heart rate variability dynamicsPDMI parasympathetice
aLF: low-frequency.
bHRV: heart rate variability.
cHF: high-frequency.
dPDMI sympathetic: principal dynamic mode index of sympathetic function.
ePDMI parasympathetic: principal dynamic mode index of parasympathetic function.
Statistical Analysis and Machine Learning
Classification
The normality of each parameter was tested using the
Kolmogorov-Smirnov test [34-36]. We tested the differences
in the parameters of transthoracic bioimpedance and heart rate
variability between control, baseline, and discharge groups,
using one-way ANOVA with Tukey posthoc for normally
distributed data and the Dunn test for nonnormally distributed
data (MATLAB, version 9.6; The Mathworks). The Dunn test
is a nonparametric analog to multiple pairwise t tests following
rejection of an ANOVA null hypothesis [37]. A P value<.05
was considered statistically significant for ANOVA and Dunn
tests.
Statistical analysis of the differences between groups provides
insight into the suitability of the measures of transthoracic
bioimpedance and heart rate variability to detect fluid
accumulation, which is used as an indication of heart failure
exacerbation. However, measurement results have nonlinear
characteristics and cannot be completely described with linear
statistical methods. Hence, we used nonlinear methods such as
machine learning to examine 15 features derived from
transthoracic bioimpedance and heart rate variability for
classification between groups (control, baseline, and discharge).
Furthermore, participants in the discharge group were partially
recovered, so they could be considered similar to the participants
in control group. We tested the feasibility of classifying
participants without fluid accumulation in the lung, termed
patients without fluid (control and discharge groups) and
participants with increased fluid in the lungs, termed patients
with fluid (baseline group)
For these classification analyses, 3 algorithms were used:
support vector machines [38], a k-nearest neighbor classifier
(k=1) [39], and decision trees [40]. Cubic, quadratic, and
Gaussian (C=1, γ=2.6) kernels were used for the support vector
machine algorithm. All combinations of the 15 parameters were
tested with the abovementioned classifiers to discriminate
control/baseline/discharge groups, and patients with
fluid/patients without fluid conditions. To compensate for the
imbalance of the classes, the prior probabilities of the classes
were set to be uniform in the training process.
Leave-one-subject-out cross-validation was used to evaluate
the performance of the machine learning models to prevent
overfitting. Accuracy was computed as the number of correct
classifications, divided by the total number of classifications
performed, which corresponds to the number of participants in
this case (N=60). Furthermore, the confusion matrices of the
best models were obtained for a more detailed analysis.
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We approached 90 patients with heart failure who were eligible,
and 43 were enrolled in this study. Out of the 43 enrolled
participants, we were able to collect data from 28 participants
with heart failure; 23 were included in the baseline group (mean
72, SD 10.7 years), and 17 were included in the discharge group
(mean 72.4, SD 9 years). Only 12 participants were included
in both baseline and discharge groups. There were several
reasons for the lower number of participants in the discharge
group: (1) in some cases, the recordings were of poor quality
(n=14); (2) some participants (n=5) were lost to follow-up (ie,
owing to a late night or weekend discharge); (3) some
participants (n=7) could not provide the second recording owing
to illness or refusal.
We enrolled 50 participants without acute decompensated heart
failure (mean 71.5, SD 8.5 years) in the control group. Of the
recordings taken on the 50 enrolled participants 32 of them were
usable. It should be noted that participants from both groups
were well matched with respect to age.
The demographic and medical characteristics of study
participants are shown in Table 2. There were no significant
differences in the demographic characteristics of the control
group compared with those of participants with heart failure
(age: P=.70; sex: P=.70; race: P=.52). Participants with acute
decompensated heart failure were more likely to have a history
of cardiovascular disease risk factors (coronary artery disease:
P=.04; myocardial infarction: P=.03), prior heart failure
(P<.001), and atrial fibrillation (P<.001). All transthoracic
bioimpedance and heart rate variability parameters were found
to be normally distributed, except for low-frequency components
of heart rate variability and high-frequency components of heart
rate variability.
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Table 2. Demographic and clinical characteristics.
P valueAcute decompensated heart failure (n=28)Control (n=32)Characteristic








.57107.8 (13.1)105.4 (14.1)Chest circumference (cm), mean (SD)
.2829.3 (6.6)27.7 (5.1)BMI (kg/m2), mean (SD)
Medical history, n (%)
.039 (32)3 (9)Myocardial infarction
.0413 (46)7 (22)Coronary artery disease
.0923 (82)20 (63)Hypertension
.503 (11)2 (6)Stroke/transient ischemic attack
<.00117 (61)1 (3)Previous diagnosis of heart failure
.567 (25)6 (19)Diabetes
.9720 (71)23 (72)Dyslipidemia
.069 (32)4 (13)Chronic lung disease
.533 (11)2 (6)Renal failure
<.00113 (46)0 (0)Atrial fibrillation
Vital signs and serum laboratories, mean (SD)
.0984.4 (25.1)75.4 (13.2)Heart rate (beats/min)
.51146.1 (28.7)141.1 (28.6)Systolic blood pressure
.7281.3 (17.3)79.9 (13.1)Diastolic blood pressure
<.00120.7 (2.8)18.3 (2.2)Respiratory rate (breaths/min)
.97138.9 (2.8)138.8 (2.4)Sodium (mg/dL)
.794.1 (0.8)4.1 (0.4)Potassium (mg/dL)
.20143.5 (80.9)121.6 (45.4)Glucose (mg/dL)
.0626.3 (18.9)19.2 (6.7)Blood urea nitrogen (mg/dL)
.151.3 (0.6)1.1 (0.4)Creatinine (mg/dL)
.141013.9 (1004.5)112.0 (76.2)B-type natriuretic peptideb
.960.2 (0.9)0.2 (1.0)Troponinb
.951.4 (0.5)1.3 (0.7)INR
Medication use, n (%)
.892 (7)2 (6)Beta blocker
.121 (4)5 (16)Angiotensin converting enzyme inhibitor
.533 (11)2 (6)Diuretic
.383 (11)6 (19)Statin
.180 (0)2 (6)Oral anticoagulant
aAsian; American Indian, or Alaska Native; Native Hawaiian or other Pacific Islander.
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bData for the control group is for 6 patients only.
We compared values of 15 parameters from transthoracic
bioimpedance and heart rate variability measurements between
participants in control, baseline, and discharge groups (Table
3). As can be noted, values of 2 parameters, R0 and R0 – R∞, for
the baseline group had statistically significantly lower values
than those for the control group, with P=.006 and P=.001,
respectively. Even though values of these 2 parameters for the
discharge group were higher than those for the baseline group,
there were no statistically significant differences (R0: P=.99;
R0 – R∞: P=.57). Possible reasons could be the lower number
of participants in the discharge group (discharge: n=17; baseline:
n=23), and one possibility is that, at the time of discharge, some
of the participants still had excess fluid in their lungs. The
parameter α for the baseline group had statistically significantly
higher values than those of the control group (P=.003),
Table 3. Values of transthoracic bioimpedance and heart rate variability parameters.
P valueDischarge (n=17), mean
(SD)






.9934.2 (17.4).00626.5 (12.8)a38.1 (10.8)R0 (Ω)
>.99954.3 (23.3)>.99952.0 (24.7)52.0 (17.0)RI (Ω)
>.9994.42·10–8 (1.85·10–8)>.9994.60·10–8 (1.71·10–8)4.08·10–8 (2.96·10–8)Cm (F)
.870.646 (0.144).0030.716 (0.121)a0.609 (0.0881)α
.565.07·10–4 (1.72·10–4).835.34·10–4 (1.51·10–4)6.11·10–4 ( 3.45·10–4)fc (Hz)
.35347 (374).51232 (389)334 (669)Fitting error (Hz)
>.99920.3 (9.1).0817.0 (7.5)21.5 (6.0)R∞ (Ω)
.5713.9 (8.8).0019.54 (6.0)a16.6 (6.1)R0– R∞ (Ω)
Heart rate variability
.0919.2 (51.3).0619.3 (43.4)3.5 (4.2)LFb HRVc
.0134.6 (57.0)a.0232.9 (55.7)a7.4 (14.4)Normalized LF HRV
.010.127 (0.085)a.380.178 (0.092)0.225 (0.134)HFd HRV
.020.371 (0.129)a.0030.391 (0.134)a0.255 (0.154)Normalized HF HRV
.5215.3 (5.98).0617.2 (12.4)11.8 (5.52)PDMI sympathetice
.1417.9 (7.56).2017.1 (10.4)13.2 (5.47)PDMI parasympatheticf
>.99974.7 (15.9)>.99974.1 (18.0)72.3 (11.9)Mean heart rate
aDenotes a statistically significant difference with respect to control group.
bLF: low-frequency.
cHRV: heart rate variability.
dHF: high-frequency.
ePDMI sympathetic: principal dynamic mode index of sympathetic function.
fPDMI parasympathetic: principal dynamic mode index of parasympathetic function.
As for the heart rate variability parameters, for the baseline and
discharge groups, high-frequency components of heart rate
variability (baseline: P=.02; discharge: P=.13) and normalized
high-frequency components of heart rate variability (baseline:
P=.003, discharge: P=.02) had significantly higher values than
those for the control group. Normalized low-frequency
components of heart rate variability exhibited a significantly
lower value in the discharge group, when compared to those in
the control group (P=.01). None of the other parameters of heart
rate variability exhibited significant differences between groups.
Tables 4 and 5 include the results for the machine learning
classification analysis. First, only transthoracic bioimpedance
parameters were used for control/baseline/discharge
classification and with fluid/without fluid classification. The
most accurate model for transthoracic bioimpedance parameters
only for classification of control/baseline/discharge was the
Gaussian support vector machine, which reached an overall
accuracy of 68% using R0, RI, and α. For patients without
fluid/patients with fluid classification using only transthoracic
bioimpedance parameters, cubic support vector machine and
gaussian support vector machine models achieved 82%
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accuracy, although the cubic support vector machine required
less parameters (R0, α, fitting error, R∞). Incorporating the heart
rate variability parameters improved the accuracy of most
models. The quadratic support vector machine model achieved
75% accuracy using 8 parameters (Cm, fc, fitting error, R∞, R0
– R∞, normalized low-frequency components of heart rate
variability, normalized high-frequency components of heart rate
variability, mean heart rate). As for patients without
fluid/patients with fluid classification, the overall best model
was the cubic support vector machine, which achieved an
accuracy of 92% using 6 parameters (R0, RI, Cm, low-frequency
components of heart rate variability, principal dynamic mode
index of parasympathetic function, mean heart rate).
Table 6 shows the confusion matrix for the most accurate model
for control/baseline/discharge classification (quadratic support
vector machine), and Table 7 shows the confusion matrix for
the most accurate model for patients without fluid/patients with
fluid classification (cubic support vector machine). In
control/baseline/discharge classification, the control and baseline
groups were correctly classified 78% and 83%, respectively.
However, the discharge group was accurately classified only in
59% of the cases. It is worth highlighting that this group was
misclassified 29% of the time as the control group. In the
patients without fluid/patients with fluid classification, the
patients without fluid condition (control and discharge groups)
were classified correctly 96% of the time, and patients with
fluid (baseline group) condition was correctly classified in 82%
of the time.
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Table 4. Highest accuracy and parameters included for control/baseline/discharge classification in each machine learning algorithm.
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aSVM: support vector machine.
bLF: low-frequency.
cHRV: heart rate variability.
dHF: high-frequency.
ePDMI sympathetic: principal dynamic mode index of sympathetic function.
fPDMI parasympathetic: principal dynamic mode index of parasympathetic function.
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Table 5. Highest accuracy and parameters included for patients without fluid/patients with fluid classification on each machine learning algorithm
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aSVM: support vector machine.
bLF: low-frequency.
cHRV: heart rate variability.
dHF: high-frequency.
ePDMI sympathetic: principal dynamic mode index of sympathetic function.
fPDMI parasympathetic: principal dynamic mode index of parasympathetic function.






Table 7. Confusion matrix for cubic support vector machine—the most accurate model for patients without fluid/patients with fluid classification.
Predicted, %Actual





In this prospective observational study, we successfully trained
machine learning models to classify participants with and
without fluid accumulation using parameters obtained with a
fluid accumulation vest, specifically transthoracic bioimpedance
and heart rate variability parameters. We achieved a
cross-validation accuracy of 92% using a cubic support vector
machine model. The transthoracic bioimpedance parameters
that contributed to this accuracy were related to intra- and
extracellular fluid, whereas the heart rate variability parameters
were mostly related to sympathetic activation. Our results
suggest that the transthoracic bioimpedance and heart rate
variability signals acquired with a wearable vest with carbon
black–PDMS dry electrodes are suitable for detecting fluid
accumulation and can potentially help with prediction and
management of clinical worsening in heart failure patients.
In the past, transthoracic bioimpedance has been used for lung
fluid abnormality detection [14,15]. In this study, we aimed to
test the feasibility of a more accurate detection method for fluid
accumulation by combining transthoracic bioimpedance and
heart rate variability, given the autonomic dysregulation
observed in heart failure patients. We used fluid accumulation
vests to capture transthoracic bioimpedance and heart rate
variability simultaneously. The accuracy of lung fluid
abnormality detection using both transthoracic bioimpedance
and heart rate variability was 92%, which is considerably higher
than the maximum accuracy achieved using either only
transthoracic bioimpedance (82%) or only heart rate variability
(76%). Although the maximum accuracy of transthoracic
bioimpedance was higher than that of heart rate variability, both
contributed to the even higher accuracy of the model that
combined them. We hypothesized that acute decompensated
heart failure participants at the time of admission (baseline
group) would have significantly lower resistances than
participants in the control and acute decompensated heart failure
discharge groups. Our results showed statistically significantly
lower R0 and R0 – R∞ resistances in the baseline group (mean
27 Ω, SD 13 Ω; mean 10 Ω, SD 6 Ω, respectively) than those
in the control group (mean 38, SD 11 Ω; mean 17, SD 6.1 Ω,
respectively), with P values of .006 and .001, respectively. This
suggests that participants in the baseline group had higher fluid
volumes retained in the lungs than participants in the control
group did. Moreover, the same parameters R0 and R0 – R∞ for
discharge participants (mean 34, SD 17 Ω; mean 14, SD 9 Ω,
respectively) were higher than those for the baseline participants.
However, this difference did not reach statistical significance
(P=.99; P=.57, respectively). Since predischarge assessments
could not be performed in all participants, our findings may be
attributable to a relatively small sample size. Alternatively,
significant variability in the amount of intrathoracic fluid
remaining before discharge may also explain our findings.
Bioimpedance is a proven biomarker of acute decompensated
heart failure. Our group previously performed a clinical study
of 106 hospitalized patients discharged after an admission for
acute decompensated heart failure. Participants were sent home
with a fluid accumulation vests and we determined that it was
feasible to measure transthoracic bioimpedance on a daily basis
[12]. We also demonstrated that a predictive algorithm analyzing
daily bioimpedance measures achieved good performance for
predicting recurrent acute decompensated heart failure [12].
Lindholm et al [22] also performed a longitudinal study
including over 500,000 participants and determined that leg
bioimpedance was inversely correlated with new-onset heart
failure and that by combining the leg bioimpedance with clinical
parameters such as age, sex, and history of myocardial
infarction, accurate prediction of heart failure could be achieved.
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In another study [23] on participants with congenital heart
disease, bioelectrical impedance correlated with heart failure
severity. In contrast to these prior studies, we sought to evaluate
the performance of intrathoracic bioimpedance measured using
a novel dry electrode for detecting acute decompensated heart
failure. We observed that participants hospitalized with acute
decompensated heart failure had lower values of intrathoracic
resistance due to higher intrathoracic fluid volume.
As for the heart rate variability, high-frequency components of
heart rate variability (at admission: P=.02; at discharge: P=.13)
and normalized high-frequency components of heart rate
variability parameters (at admission: P=.003, at discharge:
P=.02) were significantly higher in acute decompensated heart
failure participants when compared to control participants
without acute decompensated heart failure. This is possibly the
result of more labored breathing exhibited by the participants
with acute decompensated heart failure [41]. Although not
statistically significant, we observed overall higher sympathetic
activation in the acute decompensated heart failure participants,
as evidenced by higher low-frequency components of heart rate
variability (control: mean 3.5, SD 4.2; at admission: mean 19.3,
SD 43.4, P=.06; at discharge: mean 19.2, SD 51.3 P=.09). The
activation of the sympathetic nervous system is a known
countermeasure of the body aiming to restore cardiac output in
the case of heart failure [42]. Conversely, acute decompensated
heart failure participants exhibited a significantly lower
normalized low-frequency components of heart rate variability
but only in the discharge group. This was produced by the highly
elevated parasympathetic tone (high-frequency components of
heart rate variability), which affected the computation of the
normalized indices (normalized low-frequency components of
heart rate variability and normalized high-frequency components
of heart rate variability). These results corroborate the alteration
of the autonomic nervous functions produced by acute
decompensated heart failure and explain why the parameters of
the autonomic function are valuable for detecting acute
decompensated heart failure and its subsequent consequences.
In the machine learning classifications, R0 was consistently
chosen in most of the optimal models and was present in both
the most accurate models for both classifications tested in this
study (control/baseline/discharge and patients without
fluid/patients with fluid classification). This is in agreement
with the between-group statistical differences, in which this
parameter was found to be the most sensitive to heart failure.
Using the set of transthoracic bioimpedance parameters only,
machine learning models were able to provide moderate
classification accuracy for both types of classification: an
accuracy of 68% was found for 3-class classification
(control/baseline/discharge classification) model, and an
accuracy of 82% was found for 2-class models (patients without
fluid/patients with fluid classification), which are acceptable
performances, considering that the bottom line accuracy for 3-
and 2-class models are 33% and 50%, respectively. However,
adding heart rate variability parameters (the model was trained
with transthoracic bioimpedance and heart rate variability
parameters together) further increased the accuracy of the
models. The control/baseline/discharge classification, with 75%
accuracy, was acceptable. Furthermore, 92% accuracy for
classifying of patients without fluid and patients with fluid
suggested the feasibility of such an algorithm to potentially
detect the healthy condition (control group) or recovering (at
least partially) of a patient from excess fluid accumulation. This
model used parameters from transthoracic bioimpedance
(extracellular resistance, intracellular resistance, cell membrane
capacitance), as well as parameters from heart rate variability
(low-frequency components, principal dynamic mode index of
parasympathetic function, mean heart rate). The transthoracic
bioimpedance parameters that were included are related to intra-
and extracellular fluid, whereas the heart rate variability
parameters are mostly related to the sympathetic activation.
This finding is useful in developing in-home diagnostic tools
that can detect or predict fluid accumulation in heart failure
participants.
Statistical analysis and machine learning analysis showed similar
results for a reduced set of features. For instance, extracellular
resistance and low-frequency components of heart rate
variability exhibited significant differences between non–heart
failure (control) and heart failure groups (baseline and
discharge), and these features were present in the most accurate
model for fluid accumulation detection. However, other features
including intracellular resistance, cell membrane capacitance,
principal dynamic mode index of parasympathetic function, and
mean heart rate did not exhibit significant differences between
groups but were relevant for improving accuracy of the machine
learning algorithms.
Limitations
As for the limitations of the study, many recordings were not
usable, mostly in the acute decompensated heart failure group.
This is related to technical issues with the fluid accumulation
vests, which can be partially attributed to the carbon
black–PDMS electrodes. From the 28 participants with acute
decompensated heart failure, we obtained reliable measures
from only 23 participants at baseline and from 17 participants
at discharge. We obtained data from both baseline and discharge
for only 12 participants. Even in the control group, we collected
usable data from only 32 out of the 50 participants. In some
instances, applying a layer of hydrating lotion helped with data
collection. This limitation could potentially diminish the clinical
use of the device and must be addressed in the near future. A
more robust hardware design, tailored to match the impedance
of the carbon black–PDMS electrodes, is a potential
improvement. Configurations that enable collection of
transthoracic bioimpedance data from several locations on the
thorax could help the quality and usability of the data, as
accumulation of fluid does not occur always in the same
location. Furthermore, given the limited data set, we have
reported leave-one-subject-out cross-validation accuracy, and
the results cannot be interpreted as conclusive concerning the
efficacy of the transthoracic bioimpedance device and features
derived from it. Instead, the results can be interpreted as
promising, based on the validation of the transthoracic
bioimpedance and its associated features and machine learning.
A larger testing data set is required for further evaluation of
transthoracic bioimpedance to allow for more definite
conclusions about its efficacy.
JMIR Med Inform 2020 | vol. 8 | iss. 8 | e18715 | p. 15http://medinform.jmir.org/2020/8/e18715/
(page number not for citation purposes)
Reljin et alJMIR MEDICAL INFORMATICS
XSL•FO
RenderX
There are several potential clinical applications of transthoracic
bioimpedance measurements in patients with heart failure.
Wearable technologies such as fluid accumulation vests could
allow for rapid point-of-care diagnostics that could be used in
the emergency setting to help identify heart failure
decompensation. In addition, fluid accumulation vest
measurements in different clinical states such as decompensated
heart failure, predischarge, and in outpatient setting, could be
used to establish a profile for a given patient that could improve
diagnostic certainty and guide treatment. Moreover, triaging
medical severity is a necessary and time-consuming step of the
patient care process, but this is often difficult due to limitations
in both the number of available medical personnel and individual
provider time.
The device and algorithm in this study can be used in a
longitudinal study with patients with heart failure, extending
monitoring into the home. The system could be used to monitor
a patient’s fluid accumulation daily and generate early warnings
of heart failure decompensation, provide guidance on therapeutic
changes to improve quality of life, and reduce heart failure
readmissions. Alternatively, the system can be used to monitor
either the discharge readiness of a patient from the hospital or
the home treatment regime effectiveness on the patient.
Wearable sensors such as the fluid accumulation vest can
potentially provide an ideal avenue for patient monitoring over
time, allowing for rapid action in response to acute
decompensation. Garments integrating vital sign sensors have
been utilized in acute medical settings to monitor patients with
high medical risk profiles [43]. In addition, wearable
sensor-based systems for vital sign monitoring are well-received
by both patients and nursing staff with regards to usability,
further highlighting their potential role in clinical
implementation [44].
Conclusions
The main goal of this study was to evaluate the performance of
biologically relevant parameters measured by a fluid
accumulation vests with carbon black–PDMS dry electrodes.
In our clinical study (SHIELD), transthoracic bioimpedance
and heart rate variability parameters were considered for
statistical analysis and discrimination between patients with
nonacute decompensated heart failure and acute decompensated
heart failure. As expected, our results show that among the 15
parameters, 2 (extracellular resistance and
intracellular-extracellular difference in resistance) showed
statistically significantly lower values (P=.006; P=.001,
respectively), and 3 (tissue heterogeneity exponent,
high-frequency components of heart rate variability, and
normalized high-frequency components of heart rate variability)
showed statistically significantly higher values (P=.01, P=.02,
P=.003, respectively) for participants with acute decompensated
heart failure at hospital admission than those for participants in
the control group. A significant difference in the sympathetic
control (assessed with the normalized low-frequency
components, P=.01) was observed between acute decompensated
heart failure participants at the time of discharge and the control
participants. Transthoracic bioimpedance and heart rate
variability exhibited promising results for classifying
participants with excess intrathoracic fluid versus those with
normal intrathoracic fluid. Further clinical studies will be
undertaken to refine our approach and determine the optimal
application of this monitoring technology in acute medical
settings.
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ESRD: end-stage renal disease
HRV: heart rate variability
ICD: implantable cardioverter-defibrillator
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